Gcgr Phenotype Annotations

Mammalian Phenotype Ontology Annotations
Query Results - Summary

Symbol
Name
ID

Gcgr
glucagon receptor
MGI:99572

70 phenotypes from 7 alleles in 8 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Gcgr^em1Tshu/Gcgr^em1Tshu involves: C57BL/6J	decreased fasting circulating glucose level	J:279017
Gcgr^em2Smoc/Gcgr^em2Smoc C57BL/6J-Gcgr^em2Smoc	abnormal liver physiology	J:300368
	abnormal pancreatic alpha cell morphology	J:300368
	decreased body fat mass	J:300368
	decreased fasting circulating glucose level	J:300368
	improved glucose tolerance	J:300368
	increased circulating glucagon level	J:300368
	increased liver weight	J:300368
	increased pancreas weight	J:300368
	increased pancreatic alpha cell proliferation	J:300368
Gcgr^{tm1(GCGR)Kasu}/Gcgr^{tm1(GCGR)Kasu} involves: 129S7/SvEvBrd * C57BL/6J	no abnormal phenotype detected	J:58436
Gcgr^{tm1.1(KOMP)Vlcg}/Gcgr^{tm1.1(KOMP)Vlcg} C57BL/6N-Gcgr^{tm1.1(KOMP)Vlcg}/Ucd	abnormal bone structure	J:211773
	abnormal kidney morphology	J:211773
	decreased circulating insulin level	J:211773
	decreased fasting circulating glucose level	J:211773
	decreased mean corpuscular hemoglobin concentration	J:211773
	decreased total body fat amount	J:211773
	enlarged kidney	J:211773
	female infertility	J:211773
	improved glucose tolerance	J:211773
	increased blood urea nitrogen level	J:211773
	increased bone mineral content	J:211773
	increased circulating calcium level	J:211773
	increased circulating cholesterol level	J:211773
	increased kidney weight	J:211773
	increased lean body mass	J:211773
	increased liver weight	J:211773
	increased mean corpuscular volume	J:211773
	increased startle reflex	J:211773
	male infertility	J:211773
Gcgr^tm1Jcp/Gcgr^tm1Jcp DBA/1LacJ-Gcgr^tm1Jcp	abnormal exocrine gland morphology	J:176507
	abnormal pancreatic acinar cell morphology	J:176507
	abnormal pancreatic alpha cell differentiation	J:176507
	abnormal pancreatic alpha cell morphology	J:176507
	abnormal pancreatic islet morphology	J:176507
	decreased abdominal adipose tissue amount	J:176507
	decreased body weight	J:176507
	decreased circulating glucose level	J:176507
	decreased circulating insulin level	J:176507
	decreased liver weight	J:176507
	decreased subcutaneous adipose tissue amount	J:176507
	decreased susceptibility to age-related hepatic steatosis	J:176507
	decreased susceptibility to weight gain	J:176507
	enlarged pancreas	J:176507
	enlarged pancreatic islets	J:176507
	normal homeostasis/metabolism phenotype	J:73926
	increased circulating glucagon level	J:73926, J:176507
	increased glucagonoma incidence	J:176507
	increased pancreas tumor incidence	J:176507
	increased pancreatic beta cell proliferation	J:176507
	pancreatic islet hyperplasia	J:176507
Gcgr^tm1Mjch/Gcgr^tm1Mjch involves: 129 * C57BL/6J * SJL	decreased carbon dioxide production	J:216393
	decreased circulating insulin level	J:208604
	decreased food intake	J:216393
	decreased locomotor activity	J:216393
	decreased oxygen consumption	J:216393
	decreased susceptibility to diet-induced non-insulin dependent diabetes	J:216393
	decreased susceptibility to diet-induced obesity	J:216393
	improved glucose tolerance	J:208604
	increased bile salt level	J:208604
	increased circulating glucagon level	J:208604
	increased glucagon secretion	J:208604
	increased insulin sensitivity	J:208604
	increased pancreas weight	J:208604
	increased pancreatic alpha cell mass	J:208604
	increased pancreatic alpha cell number	J:208604
	increased pancreatic alpha cell proliferation	J:208604
	increased pancreatic beta cell mass	J:208604
Gcgr^tm1Mjch/Gcgr^tm1Mjch involves: 129/Sv * C57BL/6J * SJL	abnormal circulating amino acid level	J:251829
	abnormal pancreatic alpha cell morphology	J:251829
	decreased brown adipose tissue amount	J:81772
	decreased circulating glucose level	J:81772
	decreased circulating insulin level	J:251829
	decreased circulating leptin level	J:81772
	decreased gonadal fat pad weight	J:81772
	decreased interscapular fat pad weight	J:81772
	decreased litter size	J:81772
	decreased total body fat amount	J:81772
	decreased triglyceride level	J:81772
	normal endocrine/exocrine gland phenotype	J:251829
	hypoglycemia	J:81772, J:251829
	improved glucose tolerance	J:81772
	increased body mass index	J:81772
	increased circulating glucagon level	J:81772, J:251829
	increased circulating LDL cholesterol level	J:81772
	increased pancreatic alpha cell number	J:251829
	pancreatic islet hyperplasia	J:81772, J:251829
	postnatal lethality, incomplete penetrance	J:81772
	prenatal lethality, incomplete penetrance	J:81772
Gcgr^tm2.1Mjch/Gcgr^tm2.1Mjch Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ involves: C57BL/6 * DBA * SJL	abnormal glucose homeostasis	J:208604
	decreased circulating glucose level	J:208604
	decreased circulating insulin level	J:208604
	hypoglycemia	J:208604
	improved glucose tolerance	J:208604
	increased bile salt level	J:208604
	increased circulating glucagon level	J:208604
	increased insulin sensitivity	J:208604
	increased pancreas weight	J:208604
	increased pancreatic alpha cell number	J:208604
	increased pancreatic alpha cell proliferation	J:208604
	increased pancreatic beta cell mass	J:208604

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 11/19/2024 MGI 6.24